Home > Name List By other > (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine Canada

CAS No 83015-26-3 , (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine Search by region : Canada

  • Name: (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
  • Synonyms: Tomoxetina [Spanish]; Tomoxetine [INN]; (-)-Tomoxetine;(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine; CHEBI:127342; Tomoxetinum [Latin]; Tomoxetinum; Tomoxetina;Tomoxetine;
  • CAS Registry Number:
  • Flash Point: 164.1°C
  • Boiling Point: 389°C at 760 mmHg
  • Density: 1.023g/cm3
  • Refractive index: 1.552
  • Safety Statements: S22;S24/25
  • Flash Point: 164.1°C
  • Molecular Weight: 255.35474
  • InchiKey: VHGCDTVCOLNTBX-QGZVFWFLSA-N
  • InChI: InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-
    15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
  • Risk Statements: S22 :; S24/25 :;
  • Molecular Formula: C17H21NO
  • Molecular Structure:CAS No:83015-26-3 (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine

Related products

Select to

83015-26-3 (R)-TOMOXETINE HYDROCHLORIDE

  • Canada Synth?se AptoChem Inc. [Manufacturer]
  • Tel: 514-496-4252
  • Fax: 514-496-4253
  • Address: Synth?se AptoChem Inc.
    6100 Royalmount Ave
    Montreal, QC
    Canada
    H4P 2R2 null,nullCanada
Contact Supplier

Select to

1/1
References of (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
Title: Atomoxetine
CAS Registry Number: 83015-26-3
CAS Name: (gR)-N-Methyl-g-(2-methylphenoxy)benzenepropanamine
Synonyms: (-)-N-methyl-3-(o-tolyloxy)-3-phenylpropylamine; tomoxetine
Molecular Formula: C17H21NO
Molecular Weight: 255.35
Percent Composition: C 79.96%, H 8.29%, N 5.49%, O 6.27%
Literature References: Norepinephrine reuptake inhibitor. Prepn (stereochem unspec): B. B. Molloy, K. K. Schmiegel, DE 2500110; eidem, US 4314081 (1975, 1982 both to Lilly). Prepn of (R)-form: B. J. Foster, E. R. Lavagnino, EP 52492 (1982 to Lilly); Y. Gao, K. B. Sharpless, J. Org. Chem. 53, 4081 (1988). Clinical pharmacokinetics: N. A. Farid et al., J. Clin. Pharmacol. 25, 296 (1985). Binding study: D. R. Gehlert et al., J. Neurochem. 64, 2792 (1995). Biotransformation by human liver microsomes: B. J. Ring et al., Drug Metab. Dispos. 30, 319 (2002). Evaluation of abuse potential: S. H. Heil et al., Drug Alcohol Depend. 67, 149 (2002). Clinical trial in pediatric ADHD: C. J. Kratochvil et al., J. Am. Acad. Child Adolesc. Psychiatry 41, 776 (2002); and comorbid tic disorders: A. J. Allen et al., Neurology 65, 1941 (2005). Review of clinical pharmacokinetics: J.-M. Sauer et al., Clin. Pharmacokinet. 44, 571-590 (2005).
 
Derivative Type: Hydrochloride
CAS Registry Number: 82248-59-7
Manufacturers' Codes: LY 139603
Trademarks: Strattera (Lilly)
Molecular Formula: C17H21NO.HCl
Molecular Weight: 291.82
Percent Composition: C 69.97%, H 7.60%, N 4.80%, O 5.48%, Cl 12.15%
Properties: Crystals, mp 166-168° (Foster, Lavagnino). [a]D25 -38.01°; [a]36525 -177.26° (c = 1 in methanol). Also reported as white solid from acetonitrile, mp 162-164° (Gao, Sharpless). [a]D23 -41.37° (c = 1.02 in methanol); [a]D25 -40.3° (c = 0.94 in ethanol). Soly in water: 27.8 mg/ml. pKa 10.13.
Melting point: mp 166-168°; mp 162-164° (Gao, Sharpless)
pKa: pKa 10.13
Optical Rotation: [a]D25 -38.01°; [a]36525 -177.26° (c = 1 in methanol); [a]D23 -41.37° (c = 1.02 in methanol); [a]D25 -40.3° (c = 0.94 in ethanol)
 
Therap-Cat: In treatment of attention deficit hyperactivity disorder (ADHD).